Close Menu

JP Morgan Healthcare Conference

The company also announced the Infinium XT genotyping array for analyzing large sample numbers, and provided preliminary earnings for Q4 and full-year 2015.

San Francisco

Officials from Luminex and BioNano Genomics provided strategic updates at the conference.

Sequenom CEO Bill Welch said at the JP Morgan Healthcare Conference that the company plans to bring "at least" three new laboratory-developed tests to market in 2015. 

BGI's spinoff companies, BGI Tech and BGI Dx, have merged and will go public next year.

San Francisco

Officials from Exact Sciences, Cepheid, Bio-Rad, Biocartis, and NanoString provided strategic updates at the conference. 

To date, Foundation Medicine has reported approximately 35,000 tests, of which 82 percent have a clinically relevant finding.

Golden Gate Bridge

Officials from Thermo Fisher Scientific, Affymetrix, Danaher, Hologic, Genmark, and Accelerate Diagnostics provided strategic updates at the conference.

Westin St. Francis

Officials from Genomic Health and Myriad Genetics updated investors and other attendees at the conference.

CEO Jay Flatley preannounced fourth-quarter revenues of $512 million and also unveiled the HiSeq X Five System, the HiSeq 3000 and 4000 Systems, and the NextSeq 550 System, an NGS system enabled for array scanning. 

NEW YORK (GenomeWeb News) – Sequenom officials on Thursday elaborated on the firm's plans to develop a lower-cost noninvasive prenatal test for fetal aneuploidy.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.